VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 100 filers reported holding VERONA PHARMA PLC in Q3 2023. The put-call ratio across all filers is 3.08 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,206,901 | -29.5% | 74,043 | -8.5% | 0.00% | – |
| Q2 2023 | $1,710,818 | -58.6% | 80,928 | -60.7% | 0.00% | – |
| Q1 2023 | $4,134,391 | -7.5% | 205,896 | +20.3% | 0.00% | -100.0% |
| Q4 2022 | $4,471,314 | +8667.3% | 171,118 | +3337.5% | 0.00% | – |
| Q3 2022 | $51,000 | +24.4% | 4,978 | -49.1% | 0.00% | – |
| Q2 2022 | $41,000 | -12.8% | 9,785 | +3.5% | 0.00% | – |
| Q1 2022 | $47,000 | -2.1% | 9,453 | +30.1% | 0.00% | – |
| Q4 2021 | $48,000 | +6.7% | 7,268 | -11.3% | 0.00% | – |
| Q3 2021 | $45,000 | +87.5% | 8,194 | +123.0% | 0.00% | – |
| Q2 2021 | $24,000 | +84.6% | 3,674 | +144.9% | 0.00% | – |
| Q1 2021 | $13,000 | +8.3% | 1,500 | -7.9% | 0.00% | – |
| Q4 2020 | $12,000 | +33.3% | 1,628 | +8.5% | 0.00% | – |
| Q3 2020 | $9,000 | – | 1,500 | +149900.0% | 0.00% | – |
| Q1 2019 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q3 2018 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 1 | -99.5% | 0.00% | – |
| Q1 2018 | $4,000 | – | 201 | +1240.0% | 0.00% | – |
| Q4 2017 | $0 | – | 15 | +7.1% | 0.00% | – |
| Q3 2017 | $0 | – | 14 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
| Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
| Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
| Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
| Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
| NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
| Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
| Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
| ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
| Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |